Agilent gains expanded approval of diagnostic test for potential Keytruda patients
Source: SeekingAlpha
2026-06-03 10:47:35 ET
More on Agilent Technologies
- Agilent Technologies: A Solid Q2 Beat, But The Stock Remains A Hold
- Agilent Technologies, Inc. (A) Q2 2026 Earnings Call Transcript
- Agilent Technologies, Inc. 2026 Q2 - Results - Earnings Call Presentation
- These 10 large-cap U.S. healthcare companies carry the market's most expensive valuations
- Earnings Scoreboard: 11 of 12 firms smash EPS and revenue estimates and deliver Y/Y gains
Read the full article on Seeking Alpha
For further details see:
Agilent gains expanded approval of diagnostic test for potential Keytruda patients
Agilent Technologies Inc.
NASDAQ: A
A Trading
1.06% G/L:
$139.76 Last:
100,784 Volume:
$139.50 Open:
A Latest News
June 03, 2026 07:00:00 am
Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation
June 02, 2026 04:15:00 pm
Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
June 01, 2026 04:00:00 pm
How to Trade Memecoins with AI: A Beginner's Guide Using MemeToro Technology
June 01, 2026 08:00:00 am
Dallas-Based A Cash Home Buyer Announces Fast, As-Is Cash Home Buying Services for Dallas Homeowners
A Stock Data
$36,562,679,875
282,839,637
0.07%
574
N/A
Biotechnology & Life Sciences
Healthcare
US
Santa Clara
